Compare Equinor ASA (EQNR) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Hinge Health Inc. Class A Common Stock — how do they compare? Equinor ASA trades at $44.94 (market cap $107.46B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.47B). The key difference: Equinor ASA is far larger — about 12.7× Hinge Health Inc. Class A Common Stock's market cap, and Equinor ASA pays a 3.44% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EQNR | HNGE | |
|---|---|---|
Market Cap | $107.46B | $8.47B |
Volume | 3,758,208 | 1,624,526 |
Sector | Energy | Health |
52-Week High | $45.75 | $105.14 |
52-Week Low | $22.41 | $31.17 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $116.16B | $8.09B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $45.02, up 2.46% today and near its 52-week high of $45.84. The stock shows strong technical momentum with bullish moving averages and recent earnings beats in Q4 2025 and Q1 2026. Valuation metrics appear attractive with P/E of 12.2 and EV/EBITDA of 2.47. Recent news highlights expansion in LNG operations and carbon capture projects, positioning the company for growth in energy transition markets.
EQNR presents a compelling value opportunity with significant upside to the $87.50 consensus price target. Strong cash flow generation and strategic LNG expansion provide fundamental support, though declining profit margins and energy price volatility represent key risks. Analyst sentiment leans bullish with 30% buy ratings, suggesting confidence in the company's transition strategy and operational execution.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
